skills/sector-analysis/references/modules/M099-pharmaceuticals-analyst-playbook.md

<!-- Generated loss-aware reference mirror from God_Level_Public_Company_Financial_Analyst_Job_Guide_V6_99_ALL_SUB70_FIXED.docx. Canonical source remains the bundled DOCX. -->

<!-- Module: 099 | Title: Pharmaceuticals Analyst Playbook -->

## PART XV - SECTOR PLAYBOOKS | MODULE 099

# Pharmaceuticals Analyst Playbook

> Mission. Build a sector-specific research system for Pharmaceuticals that converts operating data into financial outcomes, highlights the accounting areas most likely to distort comparability, and selects valuation methods that reflect the sector's economics.

## Economic engine and binding constraints

Build product-level patients, diagnosis, penetration, price/gross-to-net, adherence, exclusivity/patent, pipeline probability, R&D, milestones, royalties, and geographic mix. Explicitly model LOE erosion and pipeline replacement needs.

## Primary KPI stack

| KPI | Construction / analyst control |
| --- | --- |
| product sales | Revenue from commercialized products recognized during the period, net of gross-to-net deductions under the relevant accounting policy. Validation: Tie the dollar measure to filed statements/footnotes; reconcile classification adjustments, one-time items, acquisitions/FX, and period consistency before using it analytically. |
| TRx/NBRx | Total prescriptions and new-brand prescriptions over the period from a consistent prescription dataset, normalized for days and channel coverage. Validation: Recalculate independently from cited source data; verify definition, period, units, scope, signs, and any reconciliation to reported financial or operating totals. |
| price | Revenue growth bridge = volume effect + price effect + mix effect + FX/acquisition effects, using a consistent base |
| gross-to-net | Gross product sales less rebates, chargebacks, discounts, returns, and other deductions divided by gross product sales. Validation: Recalculate independently from cited source data; verify definition, period, units, scope, signs, and any reconciliation to reported financial or operating totals. |
| patent life | Time remaining until key composition-of-matter, use, or regulatory exclusivity expires, adjusted for jurisdiction and expected litigation/extension outcomes. Validation: Verify start/end timestamps or periods from source records, use a consistent calendar/business-day convention, and test outliers rather than averaging them away. |
| pipeline milestones | Dated clinical, regulatory, launch, or commercial events for pipeline assets, linked to development stage, probability, and value impact. Validation: Reconcile beginning balance + additions - revenue/shipments - cancellations/adjustments to ending balance where data allow; verify cancellation rights, timing, and definition changes. |
| R&D | Research and development expense, plus material capitalized development when applicable, divided by revenue or analyzed by absolute spend and program mix. Validation: Tie the dollar measure to filed statements/footnotes; reconcile classification adjustments, one-time items, acquisitions/FX, and period consistency before using it analytically. |
| probability of success | Probability that an asset advances from its current development stage to approval/commercial success, using stage-specific base rates adjusted for asset evidence. Validation: Document scenario definitions and probabilities; verify probabilities sum appropriately, inputs are independently sourced, and sensitivity is recomputed rather than manually overridden. |



## Sector-specific accounting and comparability traps

- Milestones: reconcile issuer treatment with peer treatment and quantify the effect on reported growth, margin, cash flow, capital, or valuation before comparing outputs.

- Acquired ipr&d: reconcile issuer treatment with peer treatment and quantify the effect on reported growth, margin, cash flow, capital, or valuation before comparing outputs.

- Contingent consideration: reconcile issuer treatment with peer treatment and quantify the effect on reported growth, margin, cash flow, capital, or valuation before comparing outputs.

- Gross-to-net reserves: reconcile issuer treatment with peer treatment and quantify the effect on reported growth, margin, cash flow, capital, or valuation before comparing outputs.

- Litigation: reconcile issuer treatment with peer treatment and quantify the effect on reported growth, margin, cash flow, capital, or valuation before comparing outputs.

## Valuation frameworks

- Risk-adjusted NPV: probability-weight each asset/project cash flow by technical/regulatory/commercial success, discount by timing/risk, and subtract remaining development/funding costs.

- P/E ex pipeline: value the commercial earnings base using normalized EPS, then add separately risk-adjusted pipeline value and subtract associated development funding needs.

- Sum-of-the-parts: value each economically distinct segment with its appropriate framework, then subtract corporate costs and all non-common claims before deriving equity value.

## Sector diligence questions

- What is the most important leading indicator for Pharmaceuticals, and how many months does it lead reported revenue or cash flow?

## Sector stress and falsification

- Stress product sales and TRx/NBRx together in the direction most likely to break the equity story; flow the result through working capital, capex, liquidity, financing, dilution, and valuation.

- Explicitly test milestones. Determine whether it can make the reported sector comparison look better or worse without equivalent economic change.

## 99-point standalone execution extension

### Model architecture and forecast chain

Model prescriptions/patients, price, gross-to-net, indication, geography, patent/exclusivity, R&D, milestones, royalties, and launch curves.

### Leading-indicator dashboard

Track prescriptions, formulary access, trial readouts, competitor data, payer coverage, patent litigation, manufacturing, and regulatory milestones.

### Primary-source map

SEC filings; FDA labels, approvals, Complete Response Letters and trial databases; CMS pricing/reimbursement releases; patent/Orange Book or Purple Book data; prescription data where lawfully available.

### Accounting normalization test

Gross-to-net reserves, acquired IPR&D, collaboration revenue, contingent consideration, milestone accounting, and patent lives are critical.

### Valuation implementation

Use product-level DCF/SOTP with probability, patent cliffs, and replacement pipeline. Mature P/E alone can hide concentration.

### Worked numerical mini-case

> Illustrative product case.

100k eligible patients x 20% penetration x $40k net annual price = $800m peak revenue before persistence, ramp and gross-to-net changes. A patent loss five years earlier can remove multiple years of high-margin cash flow.

Build product-level DCF with indication-specific patients, probability, launch timing and exclusivity rather than a companywide sales multiple.

### Monitoring and falsification cadence

Breaks include clinical failure, reimbursement restriction, safety signal, patent loss, competitor superiority, or pipeline unable to replace cliffs.

At every quarterly update, rebuild the driver bridge from operating units to revenue, margin, cash flow and valuation; compare leading indicators with the prior forecast; record definition changes; and precommit the threshold that would trigger a thesis reset rather than a cosmetic estimate change.

## Sector exit standard

The Pharmaceuticals work is complete only when the analyst can explain the business in its native operating units, reproduce the KPI history, identify the binding growth constraint and marginal price setter, normalize sector-specific accounting, quantify a coherent adverse case, and translate the current market price into the operating expectations that must be met or exceeded.